Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.11
INCY's Cash to Debt is ranked lower than
79% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. INCY: 1.11 )
Ranked among companies with meaningful Cash to Debt only.
INCY' s Cash to Debt Range Over the Past 10 Years
Min: 0.35  Med: 1.19 Max: No Debt
Current: 1.11
Equity to Asset 0.24
INCY's Equity to Asset is ranked lower than
86% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INCY: 0.24 )
Ranked among companies with meaningful Equity to Asset only.
INCY' s Equity to Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.07 Max: 0.79
Current: 0.24
-1.83
0.79
Interest Coverage 4.25
INCY's Interest Coverage is ranked lower than
92% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INCY: 4.25 )
Ranked among companies with meaningful Interest Coverage only.
INCY' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 0.32 Max: 4.25
Current: 4.25
0.02
4.25
F-Score: 6
Z-Score: 11.39
M-Score: -1.30
WACC vs ROIC
11.15%
102.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 16.42
INCY's Operating margin (%) is ranked higher than
84% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. INCY: 16.42 )
Ranked among companies with meaningful Operating margin (%) only.
INCY' s Operating margin (%) Range Over the Past 10 Years
Min: -4064.53  Med: -78.07 Max: 16.42
Current: 16.42
-4064.53
16.42
Net-margin (%) 14.71
INCY's Net-margin (%) is ranked higher than
85% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. INCY: 14.71 )
Ranked among companies with meaningful Net-margin (%) only.
INCY' s Net-margin (%) Range Over the Past 10 Years
Min: -4565.45  Med: -110.46 Max: 14.71
Current: 14.71
-4565.45
14.71
ROE (%) 65.18
INCY's ROE (%) is ranked higher than
98% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. INCY: 65.18 )
Ranked among companies with meaningful ROE (%) only.
INCY' s ROE (%) Range Over the Past 10 Years
Min: 14.59  Med: 14.59 Max: 65.18
Current: 65.18
14.59
65.18
ROA (%) 12.53
INCY's ROA (%) is ranked higher than
92% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. INCY: 12.53 )
Ranked among companies with meaningful ROA (%) only.
INCY' s ROA (%) Range Over the Past 10 Years
Min: -70.43  Med: -18.85 Max: 12.53
Current: 12.53
-70.43
12.53
ROC (Joel Greenblatt) (%) 174.86
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. INCY: 174.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INCY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4727.38  Med: -376.81 Max: 174.86
Current: 174.86
-4727.38
174.86
Revenue Growth (3Y)(%) 20.70
INCY's Revenue Growth (3Y)(%) is ranked higher than
72% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. INCY: 20.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INCY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.4  Med: 19.6 Max: 194.1
Current: 20.7
-61.4
194.1
EBITDA Growth (3Y)(%) 28.60
INCY's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. INCY: 28.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
INCY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.2  Med: -8.5 Max: 219.3
Current: 28.6
-33.2
219.3
GuruFocus has detected 3 Warning Signs with Incyte Corp $INCY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

INCY Guru Trades in Q1 2016

Joel Greenblatt 52,500 sh (New)
Jim Simons 304,000 sh (New)
Paul Tudor Jones 77,400 sh (+809.20%)
Vanguard Health Care Fund 16,227,748 sh (+68.76%)
Ken Fisher 14,839 sh (+0.14%)
George Soros Sold Out
Frank Sands 3,819,401 sh (-13.61%)
Samuel Isaly 429,400 sh (-0.49%)
» More
Q2 2016

INCY Guru Trades in Q2 2016

George Soros 7,500 sh (New)
Joel Greenblatt 142,607 sh (+171.63%)
Frank Sands 4,467,286 sh (+16.96%)
Paul Tudor Jones 81,409 sh (+5.18%)
Vanguard Health Care Fund 16,227,748 sh (unchged)
Ken Fisher 14,818 sh (-0.14%)
Jim Simons 164,567 sh (-45.87%)
Samuel Isaly 363,900 sh (-15.25%)
» More
Q3 2016

INCY Guru Trades in Q3 2016

Pioneer Investments 80,822 sh (New)
Andreas Halvorsen 503,645 sh (New)
Jana Partners 58,385 sh (New)
Steven Cohen 68,000 sh (New)
John Burbank 243,396 sh (New)
Ken Fisher 14,917 sh (+0.67%)
Vanguard Health Care Fund 16,227,748 sh (unchged)
Frank Sands 4,124,074 sh (-7.68%)
Joel Greenblatt 108,099 sh (-24.20%)
George Soros 5,200 sh (-30.67%)
Jim Simons 62,900 sh (-61.78%)
Paul Tudor Jones 10,933 sh (-86.57%)
Samuel Isaly 237,999 sh (-34.60%)
» More
Q4 2016

INCY Guru Trades in Q4 2016

Ken Fisher 14,917 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:VRTX, OTCPK:ALIOY, NAS:BMRN, NAS:ALXN, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:GIFOF, OTCPK:NVZMF, OTCPK:CSLLY, NAS:ALKS, NAS:TSRO, NAS:SGEN, NAS:JAZZ, NAS:UTHR, NAS:IONS, NAS:REGN, NAS:EXEL, NAS:ARIA, NAS:TECH, NAS:ALNY » details
Traded in other countries:ICY.Germany,
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.

Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.

Top Ranked Articles about Incyte Corp

Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions Solid growth has attended the sector until this year
Against a backdrop of solid growth for the sector, the outperforming Vanguard Health Care Fund (Trades, Portfolio) replenished its portfolio in the first quarter with increases in 27 holdings and reductions or removal of 28 holdings. Read more...
Vanguard Boosts Stake in Incyte in 1st Quarter Guru sells holdings in CVS Health, Edwards Lifesciences, Monsanto
Vanguard Health Care Fund continued a streak of double-digit returns in 2015 with returns of 12.65%. That is below the fund’s returns levels of 2014 (28.52%) and 2013 (43.19%), but it is still in double digits, which was a considerable achievement in 2015’s challenging investing environment. Read more...
Frank Sands Acquires Stake in Netflix Guru adds to positions in Amazon and Under Armour
Much of the significant fourth-quarter investment activity from Frank Sands (Trades, Portfolio), CEO and CIO of Sands Capital Management, an investment management firm that invests in quality growth businesses across the globe, was in familiar names in North America. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 149.05
INCY's P/E(ttm) is ranked lower than
91% of the 246 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. INCY: 149.05 )
Ranked among companies with meaningful P/E(ttm) only.
INCY' s P/E(ttm) Range Over the Past 10 Years
Min: 100.16  Med: 283.16 Max: 5661.5
Current: 149.05
100.16
5661.5
Forward P/E 85.47
INCY's Forward P/E is ranked lower than
92% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 17.86 vs. INCY: 85.47 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 149.05
INCY's PE(NRI) is ranked lower than
91% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 28.58 vs. INCY: 149.05 )
Ranked among companies with meaningful PE(NRI) only.
INCY' s PE(NRI) Range Over the Past 10 Years
Min: 100.16  Med: 283.16 Max: 5661.5
Current: 149.05
100.16
5661.5
Price/Owner Earnings (ttm) 130.40
INCY's Price/Owner Earnings (ttm) is ranked lower than
84% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.43 vs. INCY: 130.40 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
INCY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.73  Med: 109.69 Max: 3235.14
Current: 130.4
10.73
3235.14
P/B 59.92
INCY's P/B is ranked lower than
98% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. INCY: 59.92 )
Ranked among companies with meaningful P/B only.
INCY' s P/B Range Over the Past 10 Years
Min: 40.27  Med: 78.36 Max: 391.93
Current: 59.92
40.27
391.93
P/S 22.08
INCY's P/S is ranked lower than
64% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. INCY: 22.08 )
Ranked among companies with meaningful P/S only.
INCY' s P/S Range Over the Past 10 Years
Min: 7.13  Med: 21.32 Max: 239.71
Current: 22.08
7.13
239.71
PFCF 133.20
INCY's PFCF is ranked lower than
90% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. INCY: 133.20 )
Ranked among companies with meaningful PFCF only.
INCY' s PFCF Range Over the Past 10 Years
Min: 6.56  Med: 149.16 Max: 1176.61
Current: 133.2
6.56
1176.61
POCF 80.60
INCY's POCF is ranked lower than
85% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 21.07 vs. INCY: 80.60 )
Ranked among companies with meaningful POCF only.
INCY' s POCF Range Over the Past 10 Years
Min: 6.52  Med: 84.95 Max: 775.18
Current: 80.6
6.52
775.18
EV-to-EBIT 105.89
INCY's EV-to-EBIT is ranked lower than
90% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 20.60 vs. INCY: 105.89 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8436.1  Med: -8.7 Max: 1546.6
Current: 105.89
-8436.1
1546.6
EV-to-EBITDA 83.61
INCY's EV-to-EBITDA is ranked lower than
88% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 17.09 vs. INCY: 83.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
INCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -662.5  Med: -6.6 Max: 2618.5
Current: 83.61
-662.5
2618.5
Current Ratio 3.69
INCY's Current Ratio is ranked lower than
54% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. INCY: 3.69 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.67 Max: 21.14
Current: 3.69
1.51
21.14
Quick Ratio 3.67
INCY's Quick Ratio is ranked lower than
51% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. INCY: 3.67 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.66 Max: 21.14
Current: 3.67
1.51
21.14
Days Inventory 23.77
INCY's Days Inventory is ranked higher than
86% of the 437 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. INCY: 23.77 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 14.49  Med: 122.28 Max: 323.15
Current: 23.77
14.49
323.15
Days Sales Outstanding 46.92
INCY's Days Sales Outstanding is ranked higher than
63% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. INCY: 46.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 38.86 Max: 6447.52
Current: 46.92
12.25
6447.52
Days Payable 434.88
INCY's Days Payable is ranked higher than
94% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. INCY: 434.88 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 407.13  Med: 7019.64 Max: 32457.1
Current: 434.88
407.13
32457.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.80
INCY's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. INCY: -11.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INCY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.4  Med: -7.6 Max: -0.6
Current: -11.8
-13.4
-0.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 181.15
INCY's Price/Projected FCF is ranked lower than
98% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. INCY: 181.15 )
Ranked among companies with meaningful Price/Projected FCF only.
INCY' s Price/Projected FCF Range Over the Past 10 Years
Min: 7.65  Med: 25.57 Max: 181.15
Current: 181.15
7.65
181.15
Price/Median PS Value 1.04
INCY's Price/Median PS Value is ranked lower than
55% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. INCY: 1.04 )
Ranked among companies with meaningful Price/Median PS Value only.
INCY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 0.75 Max: 9
Current: 1.04
0.11
9
Earnings Yield (Greenblatt) (%) 0.90
INCY's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. INCY: 0.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INCY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 0.7 Max: 1.3
Current: 0.9
0.1
1.3

More Statistics

Revenue (TTM) (Mil) $1,023
EPS (TTM) $ 0.79
Beta1.19
Short Percentage of Float3.82%
52-Week Range $55.00 - 121.18
Shares Outstanding (Mil)188.39

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1,106 1,545 1,702 2,097
EPS ($) 0.62 1.35 1.56 2.91
EPS w/o NRI ($) 0.62 1.35 1.56 2.91
EPS Growth Rate
(3Y to 5Y Estimate)
169.29%
Dividends Per Share ($)
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Frank Sands Acquires Stake in Netflix Feb 23 2016 
Top Insider Trades of the Past Week Feb 19 2016 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 

More From Other Websites
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended Jan 16 2017
U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment Jan 13 2017
Merck Carries Incyte On Keytruda Coattails In 4 'Hot' Tumors: Leerink Jan 13 2017
Small Caps Soar, Dow Off; Which Tech Stocks Beat Apple In Gains Today? Jan 10 2017
Incyte/Merck to Start More Epacadostat-Keytruda Studies Jan 10 2017
Jefferies Has 5 Top Biotech Stocks to Buy for 2017 Jan 10 2017
Incyte Stock Breaks Out, It And Partner Merck Will Advance Key Trial Jan 09 2017
Biotech, Chip Stocks Lift Nasdaq To Fresh Closing High Jan 09 2017
Nasdaq hits all-time high Jan 09 2017
Stocks Still Mixed, Medicals Lead Upside; Is Incyte The Next Amgen? Jan 09 2017
Chips Stocks Post Solid Gains As Nasdaq Hits New High Jan 09 2017
Merck Cancer Drug Test Sends Incyte Shares Higher Jan 09 2017
Why These Collaborations Are Important to Incyte Jan 09 2017
Biotech Stocks Surge Monday Amid Flurry of Deal Activity Jan 09 2017
How Was Incyte’s Profitability in 3Q16? Jan 09 2017
Incyte and Merck to Advance Clinical Development Program Investigating the Combination of... Jan 09 2017
What’s in Incyte’s Product Portfolio? Jan 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)